Skip to main content
PMC home page
Gut logoLink to Gut
. 2001 May;48(5):733–736. doi: 10.1136/gut.48.5.733

The promise and potential hazards of adenovirus gene therapy

L YOUNG 1, V MAUTNER 1
PMCID: PMC1728283  PMID: 11302979

Full Text

The Full Text of this article is available as a PDF (85.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amalfitano A., Hauser M. A., Hu H., Serra D., Begy C. R., Chamberlain J. S. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol. 1998 Feb;72(2):926–933. doi: 10.1128/jvi.72.2.926-933.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beier D. C., Cox J. H., Vining D. R., Cresswell P., Engelhard V. H. Association of human class I MHC alleles with the adenovirus E3/19K protein. J Immunol. 1994 Apr 15;152(8):3862–3872. [PubMed] [Google Scholar]
  3. Benihoud K., Yeh P., Perricaudet M. Adenovirus vectors for gene delivery. Curr Opin Biotechnol. 1999 Oct;10(5):440–447. doi: 10.1016/s0958-1669(99)00007-5. [DOI] [PubMed] [Google Scholar]
  4. Bergelson J. M. Receptors mediating adenovirus attachment and internalization. Biochem Pharmacol. 1999 May 1;57(9):975–979. doi: 10.1016/s0006-2952(98)00332-3. [DOI] [PubMed] [Google Scholar]
  5. Bewley M. C., Springer K., Zhang Y. B., Freimuth P., Flanagan J. M. Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR. Science. 1999 Nov 19;286(5444):1579–1583. doi: 10.1126/science.286.5444.1579. [DOI] [PubMed] [Google Scholar]
  6. Bruder J. T., Jie T., McVey D. L., Kovesdi I. Expression of gp19K increases the persistence of transgene expression from an adenovirus vector in the mouse lung and liver. J Virol. 1997 Oct;71(10):7623–7628. doi: 10.1128/jvi.71.10.7623-7628.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Burgert H. G., Kvist S. An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens. Cell. 1985 Jul;41(3):987–997. doi: 10.1016/s0092-8674(85)80079-9. [DOI] [PubMed] [Google Scholar]
  8. Cavazzana-Calvo M., Hacein-Bey S., de Saint Basile G., Gross F., Yvon E., Nusbaum P., Selz F., Hue C., Certain S., Casanova J. L. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000 Apr 28;288(5466):669–672. doi: 10.1126/science.288.5466.669. [DOI] [PubMed] [Google Scholar]
  9. Chen H. H., Mack L. M., Kelly R., Ontell M., Kochanek S., Clemens P. R. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1645–1650. doi: 10.1073/pnas.94.5.1645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dmitriev I., Krasnykh V., Miller C. R., Wang M., Kashentseva E., Mikheeva G., Belousova N., Curiel D. T. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol. 1998 Dec;72(12):9706–9713. doi: 10.1128/jvi.72.12.9706-9713.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Douglas J. T., Miller C. R., Kim M., Dmitriev I., Mikheeva G., Krasnykh V., Curiel D. T. A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nat Biotechnol. 1999 May;17(5):470–475. doi: 10.1038/8647. [DOI] [PubMed] [Google Scholar]
  12. Douglas J. T., Rogers B. E., Rosenfeld M. E., Michael S. I., Feng M., Curiel D. T. Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol. 1996 Nov;14(11):1574–1578. doi: 10.1038/nbt1196-1574. [DOI] [PubMed] [Google Scholar]
  13. Duncan S. J., Gordon F. C., Gregory D. W., McPhie J. L., Postlethwaite R., White R., Willcox H. N. Infection of mouse liver by human adenovirus type 5. J Gen Virol. 1978 Jul;40(1):45–61. doi: 10.1099/0022-1317-40-1-45. [DOI] [PubMed] [Google Scholar]
  14. Flomenberg P., Piaskowski V., Truitt R. L., Casper J. T. Characterization of human proliferative T cell responses to adenovirus. J Infect Dis. 1995 May;171(5):1090–1096. doi: 10.1093/infdis/171.5.1090. [DOI] [PubMed] [Google Scholar]
  15. Gahéry-Ségard H., Molinier-Frenkel V., Le Boulaire C., Saulnier P., Opolon P., Lengagne R., Gautier E., Le Cesne A., Zitvogel L., Venet A. Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J Clin Invest. 1997 Nov 1;100(9):2218–2226. doi: 10.1172/JCI119759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Gao G. P., Yang Y., Wilson J. M. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol. 1996 Dec;70(12):8934–8943. doi: 10.1128/jvi.70.12.8934-8943.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ginsberg H. S., Lundholm-Beauchamp U., Horswood R. L., Pernis B., Wold W. S., Chanock R. M., Prince G. A. Role of early region 3 (E3) in pathogenesis of adenovirus disease. Proc Natl Acad Sci U S A. 1989 May;86(10):3823–3827. doi: 10.1073/pnas.86.10.3823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Goldman C. K., Rogers B. E., Douglas J. T., Sosnowski B. A., Ying W., Siegal G. P., Baird A., Campain J. A., Curiel D. T. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res. 1997 Apr 15;57(8):1447–1451. [PubMed] [Google Scholar]
  19. Gooding L. R. Regulation of TNF-mediated cell death and inflammation by human adenoviruses. Infect Agents Dis. 1994 Apr-Jun;3(2-3):106–115. [PubMed] [Google Scholar]
  20. Ilan Y., Droguett G., Chowdhury N. R., Li Y., Sengupta K., Thummala N. R., Davidson A., Chowdhury J. R., Horwitz M. S. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2587–2592. doi: 10.1073/pnas.94.6.2587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kaplan J. M., St George J. A., Pennington S. E., Keyes L. D., Johnson R. P., Wadsworth S. C., Smith A. E. Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2. Gene Ther. 1996 Feb;3(2):117–127. [PubMed] [Google Scholar]
  22. Kirby I., Davison E., Beavil A. J., Soh C. P., Wickham T. J., Roelvink P. W., Kovesdi I., Sutton B. J., Santis G. Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein. J Virol. 2000 Mar;74(6):2804–2813. doi: 10.1128/jvi.74.6.2804-2813.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kochanek S., Clemens P. R., Mitani K., Chen H. H., Chan S., Caskey C. T. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5731–5736. doi: 10.1073/pnas.93.12.5731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Krasnykh V. N., Mikheeva G. V., Douglas J. T., Curiel D. T. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol. 1996 Oct;70(10):6839–6846. doi: 10.1128/jvi.70.10.6839-6846.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Lieber A., He C. Y., Kirillova I., Kay M. A. Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J Virol. 1996 Dec;70(12):8944–8960. doi: 10.1128/jvi.70.12.8944-8960.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Lollo C. P., Banaszczyk M. G., Chiou H. C. Obstacles and advances in non-viral gene delivery. Curr Opin Mol Ther. 2000 Apr;2(2):136–142. [PubMed] [Google Scholar]
  27. Lozier J. N., Metzger M. E., Donahue R. E., Morgan R. A. Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity. Blood. 1999 Dec 15;94(12):3968–3975. [PubMed] [Google Scholar]
  28. Lusky M., Christ M., Rittner K., Dieterle A., Dreyer D., Mourot B., Schultz H., Stoeckel F., Pavirani A., Mehtali M. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J Virol. 1998 Mar;72(3):2022–2032. doi: 10.1128/jvi.72.3.2022-2032.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Marshall E. Gene therapy on trial. Science. 2000 May 12;288(5468):951–957. [PubMed] [Google Scholar]
  30. Mastrangeli A., Harvey B. G., Yao J., Wolff G., Kovesdi I., Crystal R. G., Falck-Pedersen E. "Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum Gene Ther. 1996 Jan;7(1):79–87. doi: 10.1089/hum.1996.7.1-79. [DOI] [PubMed] [Google Scholar]
  31. Michael S. I., Hong J. S., Curiel D. T., Engler J. A. Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther. 1995 Nov;2(9):660–668. [PubMed] [Google Scholar]
  32. Molnar-Kimber K. L., Sterman D. H., Chang M., Kang E. H., ElBash M., Lanuti M., Elshami A., Gelfand K., Wilson J. M., Kaiser L. R. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther. 1998 Sep 20;9(14):2121–2133. doi: 10.1089/hum.1998.9.14-2121. [DOI] [PubMed] [Google Scholar]
  33. Morsy M. A., Gu M., Motzel S., Zhao J., Lin J., Su Q., Allen H., Franlin L., Parks R. J., Graham F. L. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):7866–7871. doi: 10.1073/pnas.95.14.7866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Muruve D. A., Barnes M. J., Stillman I. E., Libermann T. A. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther. 1999 Apr 10;10(6):965–976. doi: 10.1089/10430349950018364. [DOI] [PubMed] [Google Scholar]
  35. Nakatani T., Kuriyama S., Tominaga K., Tsujimoto T., Mitoro A., Yamazaki M., Tsujinoue H., Yoshiji H., Nagao S., Fukui H. Assessment of efficiency and safety of adenovirus mediated gene transfer into normal and damaged murine livers. Gut. 2000 Oct;47(4):563–570. doi: 10.1136/gut.47.4.563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Parks R. J., Chen L., Anton M., Sankar U., Rudnicki M. A., Graham F. L. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13565–13570. doi: 10.1073/pnas.93.24.13565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Parks R. J., Graham F. L. A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J Virol. 1997 Apr;71(4):3293–3298. doi: 10.1128/jvi.71.4.3293-3298.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Pereira D. S., Rosenthal K. L., Graham F. L. Identification of adenovirus E1A regions which affect MHC class I expression and susceptibility to cytotoxic T lymphocytes. Virology. 1995 Aug 1;211(1):268–277. doi: 10.1006/viro.1995.1400. [DOI] [PubMed] [Google Scholar]
  39. Rawle F. C., Knowles B. B., Ricciardi R. P., Brahmacheri V., Duerksen-Hughes P., Wold W. S., Gooding L. R. Specificity of the mouse cytotoxic T lymphocyte response to adenovirus 5. E1A is immunodominant in H-2b, but not in H-2d or H-2k mice. J Immunol. 1991 Jun 1;146(11):3977–3984. [PubMed] [Google Scholar]
  40. Rawle F. C., Tollefson A. E., Wold W. S., Gooding L. R. Mouse anti-adenovirus cytotoxic T lymphocytes. Inhibition of lysis by E3 gp19K but not E3 14.7K. J Immunol. 1989 Sep 15;143(6):2031–2037. [PubMed] [Google Scholar]
  41. Roelvink P. W., Mi Lee G., Einfeld D. A., Kovesdi I., Wickham T. J. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science. 1999 Nov 19;286(5444):1568–1571. doi: 10.1126/science.286.5444.1568. [DOI] [PubMed] [Google Scholar]
  42. Routes J. M., Bellgrau D., McGrory W. J., Bautista D. S., Graham F. L., Cook J. L. Anti-adenovirus type 5 cytotoxic T lymphocytes: immunodominant epitopes are encoded by the E1A gene. J Virol. 1991 Mar;65(3):1450–1457. doi: 10.1128/jvi.65.3.1450-1457.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Roy S., Shirley P. S., McClelland A., Kaleko M. Circumvention of immunity to the adenovirus major coat protein hexon. J Virol. 1998 Aug;72(8):6875–6879. doi: 10.1128/jvi.72.8.6875-6879.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Sijts A. J., Standera S., Toes R. E., Ruppert T., Beekman N. J., van Veelen P. A., Ossendorp F. A., Melief C. J., Kloetzel P. M. MHC class I antigen processing of an adenovirus CTL epitope is linked to the levels of immunoproteasomes in infected cells. J Immunol. 2000 May 1;164(9):4500–4506. doi: 10.4049/jimmunol.164.9.4500. [DOI] [PubMed] [Google Scholar]
  45. Smith C. A., Woodruff L. S., Kitchingman G. R., Rooney C. M. Adenovirus-pulsed dendritic cells stimulate human virus-specific T-cell responses in vitro. J Virol. 1996 Oct;70(10):6733–6740. doi: 10.1128/jvi.70.10.6733-6740.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Sterman D. H., Treat J., Litzky L. A., Amin K. M., Coonrod L., Molnar-Kimber K., Recio A., Knox L., Wilson J. M., Albelda S. M. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther. 1998 May 1;9(7):1083–1092. doi: 10.1089/hum.1998.9.7-1083. [DOI] [PubMed] [Google Scholar]
  47. Tollefson A. E., Hermiston T. W., Lichtenstein D. L., Colle C. F., Tripp R. A., Dimitrov T., Toth K., Wells C. E., Doherty P. C., Wold W. S. Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature. 1998 Apr 16;392(6677):726–730. doi: 10.1038/33712. [DOI] [PubMed] [Google Scholar]
  48. Vigne E., Mahfouz I., Dedieu J. F., Brie A., Perricaudet M., Yeh P. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J Virol. 1999 Jun;73(6):5156–5161. doi: 10.1128/jvi.73.6.5156-5161.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Von Seggern D. J., Huang S., Fleck S. K., Stevenson S. C., Nemerow G. R. Adenovirus vector pseudotyping in fiber-expressing cell lines: improved transduction of Epstein-Barr virus-transformed B cells. J Virol. 2000 Jan;74(1):354–362. doi: 10.1128/jvi.74.1.354-362.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Wickham T. J. Targeting adenovirus. Gene Ther. 2000 Jan;7(2):110–114. doi: 10.1038/sj.gt.3301115. [DOI] [PubMed] [Google Scholar]
  51. Wickham T. J., Tzeng E., Shears L. L., 2nd, Roelvink P. W., Li Y., Lee G. M., Brough D. E., Lizonova A., Kovesdi I. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol. 1997 Nov;71(11):8221–8229. doi: 10.1128/jvi.71.11.8221-8229.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Wilson C. B., Embree L. J., Schowalter D., Albert R., Aruffo A., Hollenbaugh D., Linsley P., Kay M. A. Transient inhibition of CD28 and CD40 ligand interactions prolongs adenovirus-mediated transgene expression in the lung and facilitates expression after secondary vector administration. J Virol. 1998 Sep;72(9):7542–7550. doi: 10.1128/jvi.72.9.7542-7550.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Wold W. S., Doronin K., Toth K., Kuppuswamy M., Lichtenstein D. L., Tollefson A. E. Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. Curr Opin Immunol. 1999 Aug;11(4):380–386. doi: 10.1016/S0952-7915(99)80064-8. [DOI] [PubMed] [Google Scholar]
  54. Worgall S., Wolff G., Falck-Pedersen E., Crystal R. G. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther. 1997 Jan 1;8(1):37–44. doi: 10.1089/hum.1997.8.1-37. [DOI] [PubMed] [Google Scholar]
  55. Yang Y., Nunes F. A., Berencsi K., Furth E. E., Gönczöl E., Wilson J. M. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A. 1994 May 10;91(10):4407–4411. doi: 10.1073/pnas.91.10.4407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Yang Y., Su Q., Grewal I. S., Schilz R., Flavell R. A., Wilson J. M. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J Virol. 1996 Sep;70(9):6370–6377. doi: 10.1128/jvi.70.9.6370-6377.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Yang Y., Trinchieri G., Wilson J. M. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat Med. 1995 Sep;1(9):890–893. doi: 10.1038/nm0995-890. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES